ENDP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Endo International plc

NEW YORK--()--The Law Offices of Vincent Wong reminds investors of an investigation concerning whether Endo International plc (“Endo”) (NASDAQ:ENDP) violated federal securities laws.

Click here to learn about the case: http://docs.wongesq.com/ENDP-Info-Request-Form-1642. There is no cost or obligation to you.

On June 8, 2017, the U.S. Food and Drug Administration (the “FDA”) requested Endo pull its opioid painkiller OPANA ER off the U.S. market. According to the FDA, Opana’s “high risk of abuse and potential to help spread HIV and hepatitis C” necessitated its removal from the market.

To learn more about the investigation of Endo contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/ENDP-Info-Request-Form-1642.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

The Law Offices of Vincent Wong
Vincent Wong, Esq., 212-425-1140
Fax: 866-699-3880
vw@wongesq.com

Release Summary

The Law Offices of Vincent Wong reminds investors of an investigation concerning Endo International plc

Contacts

The Law Offices of Vincent Wong
Vincent Wong, Esq., 212-425-1140
Fax: 866-699-3880
vw@wongesq.com